Abstract 13P
Background
Ovarian cancer (OC) stands as the ninth leading cause of cancer-related deaths in women and represents the most prevalent gynaecological malignancy. Patients with OC are more likely to benefit from iPARP if their tumours present deleterious mutations of BRCA1/2 genes, and if they have a homologous recombination deficiency (HRD). Somatic or germline deleterious mutations of BRCA1/2 occurs in 15 to 20 % of HRD OC. However, not all HRD cases are due to these mutations. Indeed, studies have shown that BRCA1 and RAD51C promoter methylation are responsible for 19% and 2% of HRD cases, respectively.
Methods
Two hundred and twenty-four patients with ovarian cancer were included in the ICL cohort, and 20 in the BOVARY cohort. All of them give their informed consent. DNA was extracted from FFPE tissue and cfDNA from plasma. Low-pass whole-genome sequencing was used to determine HRD status. Methylation of BRCA1 and RAD51C promoters was analysed using droplet digital PCR (ddPCR) after enzymatic conversion. A threshold of 10% was set for defining a sample as methylated.
Results
HRD status was determined for 193 of the 224 patients. A total of 77 patients were identified as HRD. Among the patients with HRD, 25 were found to have a deleterious BRCA1 or 2 mutation. Additionally, 3 patients exhibited a deleterious mutation in the RAD51C gene. After analysis of BRCA1 and RAD51C methylation in all the samples, 32 patients were identified with BRCA1 promoter methylation, while 1 patient had a RAD51C promoter methylation. All patients with promoter methylation were HRD. In the BOVARY cohort, BRCA1 promoter methylation was detected in only one HRD sample, with concordant methylation found in the paired cfDNA sample. No methylation of the RAD51C gene was found.
Conclusions
We demonstrate the feasibility of ddPCR for determining the methylation of BRCA1 and RAD51C promoters to identify patients with HRD. Furthermore, although the number of cfDNA samples analysed remains modest, our findings suggest that liquid biopsy could also be used to determine BRCA1 and RAD51C methylation statuses.
Editorial acknowledgement
Clinical trial identification
NCT03881683.
Legal entity responsible for the study
Institut de Cancérologie de Lorraine.
Funding
Tesaro.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients
Presenter: Emma Turcotte
Session: Cocktail & Poster Display session
Resources:
Abstract